Brokerages Set Moderna, Inc. (NASDAQ:MRNA) PT at $79.50

Moderna, Inc. (NASDAQ:MRNA) has earned an average recommendation of “Hold” from the twenty-one ratings firms that are presently covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $79.50.

Several research firms have weighed in on MRNA. UBS Group lowered their price target on shares of Moderna from $140.00 to $108.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. TD Cowen dropped their price target on Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a report on Friday, September 13th. Leerink Partners decreased their price objective on Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a report on Tuesday, September 17th. Barclays reduced their target price on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research report on Friday, November 8th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Friday, November 8th.

Insider Transactions at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the transaction, the insider now directly owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. The trade was a 6.71 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO James M. Mock sold 715 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. The trade was a 7.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 3,379 shares of company stock worth $158,195. Insiders own 15.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Ashton Thomas Private Wealth LLC acquired a new position in shares of Moderna during the 2nd quarter valued at $26,000. Family Firm Inc. bought a new position in shares of Moderna during the 2nd quarter worth about $33,000. Hanseatic Management Services Inc. acquired a new stake in shares of Moderna in the 2nd quarter valued at about $48,000. Plato Investment Management Ltd increased its position in Moderna by 230.4% in the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock valued at $49,000 after buying an additional 288 shares in the last quarter. Finally, Blue Trust Inc. increased its position in Moderna by 365.6% in the 3rd quarter. Blue Trust Inc. now owns 731 shares of the company’s stock valued at $49,000 after buying an additional 574 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Stock Performance

Shares of MRNA stock opened at $41.83 on Friday. The stock has a market cap of $16.10 billion, a P/E ratio of -7.19 and a beta of 1.58. The company has a fifty day moving average price of $48.26 and a two-hundred day moving average price of $83.22. Moderna has a one year low of $35.80 and a one year high of $170.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. The business had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. Moderna’s quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter last year, the company posted ($1.39) earnings per share. As a group, equities analysts predict that Moderna will post -9.3 EPS for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.